Smash hit weight-loss and diabetes drugs Wegovy and Ozempic leading the list of 15 drugs chosen for the 2nd round of federal cost settlements, which are arranged to start this year, with resulting haggled rates entering into result in 2027.

The preliminary of settlements, including 10 high-cost drugs, involved August, with resulting rates being 38 percent to 79 percent lower than sale price. Those worked out costs will enter into result in 2026 and are anticipated to conserve individuals with Medicare prescription drug protection $1.5 billion in out-of-pocket expenses.

“Last year we showed that working out for lower drug costs works,” Xavier Becerra, secretary of the Department of Health and Human Services (HHS), said in a statement. “Now we prepare to construct on that record by working out for lower rates for 15 extra essential drugs for senior citizens.”

The list of 15 drugs in the next round is below, in the order offered by HHS. According to the health department, about 5.3 million individuals with Medicare prescription drug protection utilized a minimum of among these drugs in between 2023 and 2024. Because timespan, they jointly represented about $41 billion in overall gross covered prescription drug expenses, or about 14 percent.

Topping the list are 3 variations of semaglutide drugs offered by Novo Nordisk: Wegovy, utilized for weight reduction and to decrease the dangers of heart disease; Ozempic, utilized for Type 2 diabetes; and Rybelsus, utilized for Type 2 diabetes. The drugs are as expensive as they are popular. Wegovy has a sale price of around $1,350, while Ozempic’s is almost $1,000.